Infliximab (IFX) is effective for treatment of Ulcerative Colitis (UC) and Crohn’s Disease (CD). Therapeutic drug monitoring (TDM) performed during IFX maintenance treatment with a target trough level of 3-7 ug/mL has been shown to improve clinical outcomes. Based on anti-TNF drug pharmacokinetics and post-hoc analysis from clinical trials of induction therapy, higher drug levels may be necessary early on when the disease is active. Checking post induction (week 14) trough level precludes earlier dose adjustment and may delay response to treatment during the time of higher likelihood for immunogenicity.